- Home
- DXR
as of 01-06-2026 1:41pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 61.1M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 3.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | 3.46 |
| 52 Week Low/High: | $6.55 - $14.76 | Next Earning Date: | 02-27-2026 |
| Revenue: | $66,306 | Revenue Growth: | -57.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
Chief Financial Officer
Avg Cost/Share
$0.00
Shares
3,000
Total Value
$0.00
Owned After
20,050
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$0.00
Shares
18,000
Total Value
$0.00
Owned After
53,908
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$0.00
Shares
2,344
Total Value
$0.00
Owned After
17,616
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Michel Robert J | DXR | Chief Financial Officer | Dec 9, 2025 | Buy | $0.00 | 3,000 | $0.00 | 20,050 | |
| Feldschuh Jonathan Adam | DXR | Chief Scientific Officer | Dec 9, 2025 | Buy | $0.00 | 18,000 | $0.00 | 53,908 | |
| Jefferies John | DXR | Chief Medical Officer | Nov 12, 2025 | Buy | $0.00 | 2,344 | $0.00 | 17,616 |
Compare DXR vs Leading Stocks
See how DXR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.